4 min read
ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
Join Veristat and other Oncology researchers, clinicians and patients at the ESMO 2016 Conference, focused on finding the most effective cancer treatment solutions available today. ESMO 2016 offers a top-notch scientific and educational program created by international experts in oncology. Some key topic areas include:
Veristat’s Theresa Bruce and Kath Clayton will be attending ESMO and will be on hand to discuss how Veristat can help you design and execute your cancer trials throughout Europe and North America.
Veristat has helped clients run hundreds of oncology clinical trials for novel drugs, biologics, vaccines, immuno-therapies and diagnostics. We know that even the simplest of clinical trials tasks are much more complex and requires skilled expertise to complete. Schedule a time to speak with Veristat at ESMO about the challenges you are trying to overcome with your oncology program.
4 min read
Jun 15, 2026 Veristat News
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
10 min read
Jun 12, 2026 Veristat Blog
This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...